Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 6/20 | 0.34 |
| ▸ | BCHE | P06276 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31612244 | 1.00 | ALDH1A1 (0.37) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL7822399 | 0.98 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL11722926 | 0.79 | CYP1A2 (0.50) | ALDH1A1HSD17B10HIF1ACYP1B1CYP3A4 | |
| Hydrochloric Acid SCHEMBL11721589 | 0.78 | CYP1A2 (0.48) | CYP3A4MAPTCYP1A2 | |
| Bromide SCHEMBL11727587 | 0.78 | CYP1A2 (0.48) | ALDH1A1CYP3A4MAPTCYP1A2ACHE | |
| Bromide SCHEMBL11725158 | 0.76 | PTPN22 (0.51) | ALDH1A1HSD17B10HIF1ACYP1B1CYP3A4 | |
| Bromide SCHEMBL11728184 | 0.76 | NQO2 (0.50) | ALDH1A1CYP3A4MAPTCYP1A2 | |
| SCHEMBL27734270 | 0.76 | BCL2L1 (0.40) | ALDH1A1HSD17B10TSHRTDP1HIF1A | |
| SCHEMBL29480988 | 0.76 | BCL2L1 (0.40) | ALDH1A1HSD17B10TSHRTDP1HIF1A | |
| Bromide SCHEMBL11723738 | 0.75 | CYP1A2 (0.41) | ALDH1A1HSD17B10MAPTTP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4042592-A | ANTISARCOMA GROWTH | KANEBO, LTD. (JA) | 1977-08-16 | — | — | US | claimed |
| US-20230172916-A1 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | ELEONOR (BE) | 2023-06-08 | — | — | US | disclosed |
| US-20230172916-A1 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | ELEONOR (BE) | 2023-06-08 | — | — | US | disclosed |
| US-20230024933-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4055164-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin (DE) | 2022-09-14 | — | — | EP | disclosed |
| US-11331333-B2 | Treatment of aberrant fibroblast proliferation | Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20210137963-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2021-05-13 | — | — | US | disclosed |
| US-20110015137-A1 | RECA INHIBITORS AND THEIR USES AS MICROBIAL INHIBITORS OR POTENTIATORS OF ANTIBIOTIC ACTIVITY | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2004847-A2 | OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS | Pentabase Aps (DK) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007104318-A2 | OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS | PENTABASE APS (DK) | 2007-09-20 | — | — | WO | disclosed |
| EP-1140930-A1 | DIBENZO a,g]QUINOLIZINIUM DERIVATIVES AND THE SALTS THEREOF | HANWHA CHEMICAL CORPORATION (KR) | 2001-10-10 | — | — | EP | disclosed |
| EP-0888346-B1 | CORALYNE ANALOGS AS TOPOISOMERASE INHIBITORS | UNIV RUTGERS (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000037468-A1 | DIBENZO[a,g]QUINOLIZINIUM DERIVATIVES AND THE SALTS THEREOF | HANWHA CHEMICAL CORPORATION (KR) | 2000-06-29 | — | — | WO | disclosed |
| US-6030979-A | INHIBITS THE STEROL 14-REDUCTASE WHICH CATALYZES THE BIOSYNTHESIS OF CHOLESTEROL FROM LANOSTEROL; ANTICHOLESTEROL AND-LIPEMIC AGENTS | HANWHA CORPORATION (CN) | 2000-02-29 | — | — | US | disclosed |
| US-6028197-A | ENZYME INHIBITORS INHIBITING THE STEROL 14-REDUCTASE WHICH IS INVOLVED IN THE DISTAL PATHWAY OF CHOLESTEROL BIOSYNTHESIS, AND THE USE AS ANTICHOLESTEROL AGENTS OR ANTILIPEMIC AGENTS | HANWHA CORPORATION (KR) | 2000-02-22 | — | — | US | disclosed |
| US-6028197-A | ENZYME INHIBITORS INHIBITING THE STEROL 14-REDUCTASE WHICH IS INVOLVED IN THE DISTAL PATHWAY OF CHOLESTEROL BIOSYNTHESIS, AND THE USE AS ANTICHOLESTEROL AGENTS OR ANTILIPEMIC AGENTS | HANWHA CORPORATION (KR) | 2000-02-22 | — | — | US | disclosed |
| EP-0888346-A1 | CORALYNE ANALOGS AS TOPOISOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997029106-A1 | CORALYNE ANALOGS AS TOPOISOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1997-08-14 | — | — | WO | disclosed |
| US-4042592-A | ANTISARCOMA GROWTH | KANEBO, LTD. (JA) | 1977-08-16 | — | — | US | disclosed |
| US-4042592-A | ANTISARCOMA GROWTH | KANEBO, LTD. (JA) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015137-A1 | RECA INHIBITORS AND THEIR USES AS MICROBIAL INHIBITORS OR POTENTIATORS OF ANTIBIOTIC ACTIVITY | CGAS, RPIA, CLPP | ALDH1A1 4007/4885HSD17B10 4274/4885CYP2A6 2644/4885 |
| US-20230024933-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | EYA2, EYA3, PTP4A1 | ALDH1A1 1222/4885HSD17B10 3826/4885CYP2A6 4212/4885 |
| US-20210137963-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | EYA2, EYA3, PTP4A1 | ALDH1A1 1222/4885HSD17B10 3826/4885CYP2A6 4212/4885 |
| US-11331333-B2 | Treatment of aberrant fibroblast proliferation | EYA2, EYA3, PTP4A1 | ALDH1A1 1222/4885HSD17B10 3826/4885CYP2A6 4212/4885 |
| US-20230172916-A1 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | MANBA, CROCC, MAN2A1 | ALDH1A1 3271/4885HSD17B10 2328/4885CYP2A6 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.